Several studies on human patients with SARS-CoV, MERS-CoV and SARS-CoV-2 indicate that there is a limited or delayed induction of the type-I and type-III IFN responses and that this has negative consequences as it allows for increased viral loads [63,64,65], while others have shown a robust activation of the IFN response in COVID-19 patients [66]. The gene discussed is IFNA1; the disease is COVID-19.